Valuation: Epigenomics AG

Market Cap 8L 9L 7L 7L 12.9L 8.87Cr 12.96L 88.55L 34.36L 4.49Cr 34.91L 34.15L 15Cr P/E 2024
-0.29x
P/E 2025 -2.51x
Enterprise Value 1.18Cr 1.37Cr 1.1Cr 1.01Cr 1.9Cr 130.82Cr 1.91Cr 13Cr 5.07Cr 66Cr 5.15Cr 5.03Cr 218.39Cr EV / Sales 2024
-
EV / Sales 2025 490x
Free-Float
70.75%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal 55 01/02/2024
Director TitleAgeSince
Chairman 58 01/03/2023
Director/Board Member 55 01/06/2020
Director/Board Member 56 05/02/2024
Change 5-day change 1-year change 3-year change Capi.($)
-0.34%+6.51%+106.47%+324.68% 418.94Cr
-4.27%+14.94%+219.37%+31.38% 382.31Cr
+0.57%+8.87%+49.88%+74.16% 354.04Cr
+0.31%+10.35%+299.69%+483.73% 262.81Cr
-2.91%+4.01%-26.20%-20.95% 232.32Cr
+1.52%+4.01%+32.48% - 150.32Cr
-1.11%+55.05%+270.83%-14.42% 134.09Cr
-2.18%+3.80%+19.81%+45.60% 103.48Cr
+1.68%+22.01%+34.48%+180.72% 68Cr
Average -0.20%+15.96%+111.87%+138.11% 234.02Cr
Weighted average by Cap. -0.15%+13.43%+125.53%+159.31%

Financials

2024 2025
Net sales - 24T 27.97T 22.52T 20.57T 38.81T 26.69L 38.96T 3L 1L 13.49L 1L 1L 44.55L
Net income -33.52L -39.07L -31.45L -28.73L -54.2L -37Cr -54.42L -3.72Cr -1.44Cr -19Cr -1.47Cr -1.43Cr -62Cr -3L -4L -3L -3L -5L -3.49Cr -5L -34.84L -13.52L -1.76Cr -13.74L -13.44L -5.83Cr
Net Debt 1.05Cr 1.22Cr 98.1L 89.62L 1.69Cr 116.25Cr 1.7Cr 12Cr 4.5Cr 59Cr 4.57Cr 4.47Cr 194.07Cr 1.1Cr 1.28Cr 1.03Cr 94.01L 1.77Cr 121.95Cr 1.78Cr 12Cr 4.72Cr 62Cr 4.8Cr 4.69Cr 203.57Cr
Logo Epigenomics AG
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Employees
-